New Pancreatic Cancer Drug Reduces Risk of Death by 60 Percent

Researchers say the findings mark one of the most promising advances in pancreatic cancer treatment in decades.

ART-ur/Shutterstock

A new drug for one of the deadliest cancers nearly doubled patient survival in a major clinical trial.

The drug, daraxonrasib, developed by Revolution Medicines, targets a genetic mutation called RAS, which drives tumor growth in more than 90 percent of pancreatic cancer cases.